Abstract
e21011 Background: Lung cancer is one of the leading causes of cancer related deaths worldwide and India. The understanding of the molecular basis of lung cancer has led to increased number of FDA approved targeted therapies and therefore survival. Data on the molecular landscape of lung cancers has a preponderance of western and east Asia. India while may harbour one third of world new lung cancer case, the understanding of comprehensive molecular landscape of lung cancer in India is poor. Methods: We have retrospectively compared comprehensive genomic profiling of lung cancer patients across three centres over a period of two years using foundation one cdx. We aim to compare this to available data from rest of the world and present the differences and commonalities. We believe this will help understand both differences in presentations and pattern of disease as well as question if treatment algorithms should be same or different. At least on this occasion we will limit our study to foundation one CDx patients only so that comparison with western data is not confounded by differences in technology. Results: We have Highlighted 44 such patients and will be comparing their data to the available data on foundation on CDX from available literature. 27 (61.3%) patients had one of the most common targetable mutations including EGFR ALK ROS MET BRAF ERBB2 and NTRK. Surprisingly 9(20.4%) had mutations in the homologus repair pathway. 3 patients also had MSI High. We will present comparison of this Indian data to that's available across the world. Conclusions: Precision Oncology and molecular biology is cornerstone of cancer care especially in Lung Cancer. We want to deepen the understanding of the comparison of Indian cohort and believe its different with arguably more targetable abnormalities detected than in the west and similar to the eastern population of the world.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
